If you have been reading about HPLC-MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
=== Controlled release of therapeutics === The ability of aptamers to reversibly bind molecules such as proteins has generated increasing interest in using them to facilitate controlled release of therapeutic biomolecules, such as growth factors. This can be accomplished by tuning the binding strength to passively release the growth factors, along with active release via mechanisms such as hybridization of the aptamer with complementary oligonucleotides or unfolding of the aptamer due to cellular traction forces.
=== Distribution ratio === In solvent extraction, a distribution ratio (D) is often quoted as a measure of how well-extracted a species is. The distribution ratio is a measure of the total concentration of a solute in the organic phase divided by its concentration in the aqueous phase. The partition or distribution coefficient (Kd) is the ration of solute concentration in each layer upon reaching equilibrium. This distinction between D and Kd is important. The partition coefficient is a thermodynamic equilibrium constant and has a fixed value for the solute’s partitioning between the two phases. The distribution ratio’s value, however, changes with solution conditions if the relative amounts of A and B change. If we know the solute’s equilibrium reactions within each phase and between the two phases, we can derive an algebraic relationship between Kd and D. The partition coefficient and the distribution ratio are identical if the solute has only one chemical form in each phase; however, if the solute exists in more than one chemical form in either phase, then Kd and D usually have different values. Depending on the system, the distribution ratio can be a function of temperature, the concentration of chemical species in the system, and a large number of other parameters. Note that D is related to the Gibbs Free Energy (ΔG) of the extraction process. In solvent extraction, two immiscible liquids are shaken together. The more polar solutes dissolve preferentially in the more polar solvent, and the less polar solutes in the less polar solvent.
=== 2018 American consulate bombing === On 2 December 2018, at approximately 7:30 CST, two grenades were thrown onto consular grounds in Guadalajara, with one of them exploding and causing a 16-inch (approximately 40 cm) hole in the wall of the building. At the time of the bombing, the consulate general office was closed and no injuries were sustained. It is unconfirmed if the attack was carried out by a cartel.
Sources: en.wikipedia.org
== History == Harith Rajagopalan, MD, PhD, and Jay Caplan established Fractyl Health, initially named Fractyl Laboratories, in 2010. The company's Revita device gained CE marking in April 2016 and became commercially available in the UK in January 2020. In April 2021, the US Food and Drug Administration (FDA) gave Revita breakthrough device designation to treat type 2 diabetes. The company changed its name to Fractyl Health in June 2021. In April 2022, the FDA approved an investigational device exemption trial for Revita. It became available commercially in Germany in early 2023. The FDA issued additional breakthrough device designation to Revita in July 2024 for weight maintenance in certain people with type 2 diabetes or obesity. Fractyl had an initial public offering on the Nasdaq in February 2024. As of February 2025, the company's REMAIN-1 study is evaluating Revita for patients with obesity to support weight maintenance after use of a GLP-1 drug. In January 2025, Fractyl announced it would focus research for Revita on obesity and people on GLP-1s, citing rising demand driven by the popularity of GLP-1s. The company also laid off some employees focused on type 2 diabetes treatment.
== Tethelin (Roberson's patent and trade-mark) == In March 1916, Robertson published a suite of five interconnected articles in the Journal of Biological Chemistry, describing the process through which a material, which he called tethelin (from τεθηλώς, 'growing'), he and his assistant, Louis Adolph Ray (1886-1960), had extracted (in 1915) from the anterior lobes of ox pituitaries acquired from a local slaughterhouse (BR.22), and its positive effects on the growth of his experimental mice (BR.23–BR.26). Robertson claimed that the substance was the pituitary's "growth-controlling principle"; and, according to Robertson's account, on-going research demonstrated that tethelin not only controlled growth, but was very effective in the treatment of ulcers of long standing and slow-healing wounds. Prior to the (March 1916) publication of his discoveries, Robertson had not only been granted the US patent (BR.18) and the UK patent (BR.19) for the "Tethelin" extraction process, but had also begun to use the trade-mark TETHELIN, the rights to which he was subsequently granted in December 1916 (BR.21). Well aware of Jokichi Takamine's earlier struggle to patent adrenalin, and the challenges and time delays Takamine experienced, Robertson simply patented his process, and not his product.
Kerry-Lynne Donna Findlay (born January 12, 1955) is a Canadian politician and lawyer who served as leader of the Conservative Party of British Columbia from May to September 2026. She had served as a member of Parliament (MP) for South Surrey—White Rock from 2019 to 2025 and Delta—Richmond East from 2011 to 2015 with the federal Conservative Party. Findlay was Associate Minister of National Defence in 2013, and Minister of National Revenue from 2013 to 2015 under Prime Minister Stephen Harper.
Oxygenated blood then returns to the left atrium, passes through the left ventricle and is pumped out through the aorta into systemic circulation, traveling through arteries, arterioles, and capillaries—where nutrients and other substances are exchanged between blood vessels and cells, losing oxygen and gaining carbon dioxide—before being returned to the heart through venules and veins. The adult heart beats at a resting rate close to 72 beats per minute. Cardiovascular diseases are the most common cause of death globally; an estimated 19.8 million people died from them in 2022, representing about 32% of all deaths worldwide. Of these, 85% were due to heart attack and stroke. Risk factors include: smoking, being overweight, little exercise, high cholesterol, high blood pressure, and poorly controlled diabetes, among others. Cardiovascular diseases do not frequently have symptoms but may cause chest pain or shortness of breath. Diagnosis of heart disease is often done by the taking of a medical history, listening to the heart-sounds with a stethoscope, as well as with ECG, and echocardiogram which uses ultrasound. Specialists who focus on diseases of the heart are called cardiologists, although many specialties of medicine may be involved in treatment.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.